There is going to be an antidote for all types of snakes

There are already antidote for snake bites, but depending on the type of snake, there will be a specialized medicine, and it must be kept cold to be used, so if it is far from the hospital or the solid type cannot be determined, the mortality rate is high.

This is about to be solved by US scientists who say it has succeeded in creating a drug that can cure all types of snake venom (currently 28 common toxins) and patients with can be used without the help of a doctor.

One of the most difficult things in the development of snake venom is depending on the type of poison of different snakes, its impact on the human body is different , possibly causing paralysis, tissue damage. , blood or all three effects. Therefore, an effective antidote should counteract all biochemical reactions caused by snake venom to humans. To do this, a team of researchers at the California Institute of Science led by Professor Matt Lewin focused on an enzyme called sPLA 2 that has just been found in snake venom, which has been created in the human body too. Anti-inflammatory process.

Varespladib has the effect of inhibiting the venom activity of all types of snakes.

The team collected chemical compounds to conduct tests against sPLA2 in clinical trials in a variety of conditions. Next they mixed the toxic and antidote and used a color indicator to measure the concentration of sPLA2 contained in the mixture. Eventually they discovered a drug that carries varespladib that inhibits the action of sPLA2 . This drug was previously developed to prevent wound infection.

To verify the effectiveness, Lewin used varespladib to combat a series of 28 different types of snake venom, including black mamba snakes, butterfly cobra, Indian tigers, South African tigers, snakes, snakes. Inland Taipan, coral snakes, South American rattlesnakes and sea-snakes. And the results show that the activity of sPLA2 is inhibited in these cases. At the same time, the results all work when tested on mice, helping to inhibit the activity of sPLA2, keeping mice alive after being bitten.

Although the results of the first tests are promising, research has yet to be published in major journals, and not yet reviewed by other scientists. The reason is that they think that this is only the initial success and still have to do a lot of other tests before launching a versatile antidote. However, if successful, this will be good news for all people, especially in tropical and remote areas.